WuXi Biologics' MFG8 drug substance manufacturing facility in Hebei passed the FDA's Pre‑License Inspection (PLI), clearing a key regulatory hurdle for commercial‑scale production. The clearance enables WuXi to move toward commercial supply of a promising autoimmune therapy, potentially boosting revenue and strengthening its position as a leading CDMO. Who is involved: WuXi Biologics, U.S. Food and Drug Administration (FDA), and the unnamed partner developing the autoimmune therapy.. Likely next: Final product authorization for the therapy, scale‑up of commercial manufacturing at MFG8, and subsequent market launch or partnership announcements.. WuXi Biologics announced that its MFG8 drug substance manufacturing site in Hebei has successfully passed the FDA's Pre‑License Inspection (PLI). This milestone clears a key regulatory hurdle for the site to produce drug substance at commercial scale for a potential blockbuster autoimmune therapy. The approval positions WuXi to move forward with final product authorization and large‑scale manufacturing.
INTELLIGENCE
Social Pulse
AI estimate · not scraped